Pinned Tweet
BETA Technologies: Heading for a meltdown
Is $BETA the $NKLA of this cycle, but with a Jeffrey Epstein twist?
Please read our presentation and the disclaimer to learn more:
gothamcityresearch.com/post/…
Replying to @GothamResearch
You forgot to mention that the most important parts of BETA’s company are headed by the CEO’s wife who has zero experience in aviation.
Disturbingly, employees refer to her as “mother” according to multiple interviews. This is a very twisted company.
Finally, the Jeffrey Epstein twist.
ARMI is a Related party, paid BETA $17.8mln, which amounts to 59% of BETA’s FY23-24 revenue.
Dean Kamen leads ARMI, is big $BETA shareholder, & former BETA Board member. Kamen has ties to Jeffrey Epstein that led him to resign from BETA:
$BETA touts its "$4B backlog" as a key performance indicator, yet this $4,000 million "backlog" is only backed by $5 million of aircraft deposits, or 0.1% of the reported "backlog". It is the most suspicious use of the word "backlog" we've ever seen in a public company.
3
9
4,400
Perhaps the $5 million aircraft deposit figure is a more accurate measure for what people traditionally interpret "backlog" to mean.
Take for example, the fact that $BETA’s reported backlog contains suspect orders from customers in financial distress:
3
1,660
$BETA has never sold a single aircraft, yet the Street EXPECTS BETA’s FY 28 sales to surpass the Cirrus SF50 Vision,the aviation industry’s best-selling jet, by a factor of 10x. We find this suspect because:
BETA has a history of missing certification timelines many times (1/x)
$BETA CEO Kyle Clark claims: “We don't mark our progress until our partners at the FAA have accepted and approved our work”
Yet some of BETA’s slides appear to show submitted work by BETA, and others match neither measure, contrary to the CEO's claims:
1
3
1,531
$BETA promotes their recent “Special Airworthiness Market Survey Certificate” as meaningful milestones
But a “Special Airworthiness Market Survey Certificate” doesn't mean any progress toward actual FAA approval
In fact, industry execs warn against overstating their importance:
1,267
Not only did $BETA misrepresent its CX300 as having a 336 nm range (it was the A250 Model that flew 336),
the 336 nm range test flight happened only once out of 3,913 test flights.
In fact, nearly all of BETA’s test flights fall within the 50-150 n.m. range.
We will be discussing a new idea today at Sohn London. Stay tuned.
sohnconference.org/london-co…
Sumitomo Chemical and Sumitomo Pharmaceutical: Part II CiRA, Dr. Yamanaka, and the undisclosed history of image duplication concerns
gothamcityresearch.com/post/…
CiRa, led by Shinya Yamanaka, is Sumitomo Pharma's research partner for the Amchepry program. There is a history of suspect research and fraud, particularly repeated behavior of 'image duplication concerns'.
We found 2 well documented cases of fraud, but 8 that are undisclosed
Cc: @addictedtoigno1 David Sholto. Didn’t realize who Sholto was but learned he is a scientist who has a talent for detecting research fraud.
It’s not surprising @4BetterScience mentions Yamanaka (and not in a good way) multiple times.
That these scientists are critical of Yamanaka is red flag re: Sumitomo Pharma
2
3,279
CiRa's President Yamanaka (President of Sumitomo Pharma's key research partner) paper from 2011:
Modeling familial Alzheimer's disease with induced pluripotent stem cells
Similarly to the 2000 Yamanaka paper scandal, a user by the name of David Sholto noted similarity within 2 images of the paper of which Yamanaka is listed as an author.
Source: pubpeer.com/publications/0B7…
These are conflicts of interest, but they are not problematic by themselves. The issue is that CiRA and its head Dr. Yamanaka have two documented cases of fraud. Worse, we have discovered 8 additional cases where we see fraud, including a paper where the Amchepry trial’s lead investigator is an author. For these reasons, and more, we believe the Amchepry and regenerative research are compromised and the 350 revenue target, bogus.
1
2
1,129













